New product – from Galenica

Galenica AB has developed and is launching Ovixan®, a cream formulation for the treatment of psoriasis and eczema. The clinical development program has been successfully completed and the product was approved in all the Nordic countries during Q1 2012. The trade name (Ovixan, a prescription drug) has been registered and patents are pending. The new and improved cream preparation, which is indicated for both psoriasis and eczema, will offer a number of patient benefits compared to existing cream formulations leading to improved compliance. Galenica will launch the product in all the Nordic countries during 2012–13. For more information about Ovixan please see the ”SUMMARY OF PRODUCT CHARACTERISTICS” or